inspire medical systems inc - INSP
INSP
Close Chg Chg %
65.64 0.02 0.03%
Closed Market
65.66
+0.02 (0.03%)
Volume: 1.26M
Last Updated:
Feb 6, 2026, 3:59 PM EDT
Company Overview: inspire medical systems inc - INSP
INSP Key Data
| Open $65.84 | Day Range 64.77 - 67.45 |
| 52 Week Range 64.77 - 197.61 | Market Cap $1.98B |
| Shares Outstanding 29.06M | Public Float 27.76M |
| Beta 0.74 | Rev. Per Employee N/A |
| P/E Ratio 44.99 | EPS $1.50 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.26M |
INSP Performance
| 1 Week | -13.30% | ||
| 1 Month | -33.22% | ||
| 3 Months | -19.67% | ||
| 1 Year | -63.93% | ||
| 5 Years | -70.44% |
INSP Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
19
Full Ratings ➔
About inspire medical systems inc - INSP
Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. It operates through the United States and All Other Countries geographical segments. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
INSP At a Glance
Inspire Medical Systems, Inc.
5500 Wayzata Boulevard
Golden Valley, Minnesota 55416
| Phone | 1-844-672-4357 | Revenue | 802.80M | |
| Industry | Medical Specialties | Net Income | 53.51M | |
| Sector | Health Technology | 2024 Sales Growth | 28.49% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,246 | |
| View SEC Filings |
INSP Valuation
| P/E Current | 44.993 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 105.817 |
| Price to Sales Ratio | 7.053 |
| Price to Book Ratio | 7.994 |
| Price to Cash Flow Ratio | 43.47 |
| Enterprise Value to EBITDA | 123.106 |
| Enterprise Value to Sales | 6.538 |
| Total Debt to Enterprise Value | 0.006 |
INSP Efficiency
| Revenue/Employee | 644,304.976 |
| Income Per Employee | 42,944.623 |
| Receivables Turnover | 8.626 |
| Total Asset Turnover | 1.081 |
INSP Liquidity
| Current Ratio | 7.128 |
| Quick Ratio | 6.222 |
| Cash Ratio | 5.034 |
INSP Profitability
| Gross Margin | 84.68 |
| Operating Margin | 4.495 |
| Pretax Margin | 7.281 |
| Net Margin | 6.665 |
| Return on Assets | 7.206 |
| Return on Equity | 8.479 |
| Return on Total Capital | 7.416 |
| Return on Invested Capital | 8.125 |
INSP Capital Structure
| Total Debt to Total Equity | 4.61 |
| Total Debt to Total Capital | 4.407 |
| Total Debt to Total Assets | 3.933 |
| Long-Term Debt to Equity | 4.355 |
| Long-Term Debt to Total Capital | 4.163 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Inspire Medical Systems Inc - INSP
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 233.39M | 407.86M | 624.80M | 802.80M | |
Sales Growth
| +102.28% | +74.75% | +53.19% | +28.49% | |
Cost of Goods Sold (COGS) incl D&A
| 33.28M | 66.11M | 96.58M | 122.99M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.99M | 2.90M | 2.85M | 6.55M | |
Depreciation
| 1.99M | 2.90M | 2.85M | 6.55M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +88.84% | +98.67% | +46.07% | +27.35% | |
Gross Income
| 200.12M | 341.74M | 528.22M | 679.82M | |
Gross Income Growth
| +104.70% | +70.77% | +54.57% | +28.70% | |
Gross Profit Margin
| +85.74% | +83.79% | +84.54% | +84.68% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 239.97M | 389.33M | 568.49M | 643.74M | |
Research & Development
| 37.35M | 68.64M | 116.54M | 114.13M | |
Other SG&A
| 202.62M | 320.69M | 451.96M | 529.61M | |
SGA Growth
| +55.86% | +62.25% | +46.02% | +13.24% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (39.85M) | (47.59M) | (40.27M) | 36.08M | |
Non Operating Income/Expense
| 8.00K | 5.00M | 20.36M | 22.39M | |
Non-Operating Interest Income
| 125.00K | 5.05M | 20.56M | 23.25M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 2.13M | 1.68M | 22.00K | |
Interest Expense Growth
| - | +0.52% | -21.19% | -100.00% | |
Gross Interest Expense
| - | 2.13M | 1.68M | 22.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (41.97M) | (44.27M) | (19.91M) | 58.45M | |
Pretax Income Growth
| +26.48% | -5.48% | +55.03% | +393.65% | |
Pretax Margin
| -17.98% | -10.85% | -3.19% | +7.28% | |
Income Tax
| 72.00K | 613.00K | 1.25M | 4.94M | |
Income Tax - Current - Domestic
| 23.00K | 342.00K | 644.00K | 4.10M | |
Income Tax - Current - Foreign
| 49.00K | 271.00K | 603.00K | 854.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | (13.00K) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (42.04M) | (44.88M) | (21.15M) | 53.51M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (42.04M) | (44.88M) | (21.15M) | 53.51M | |
Net Income Growth
| +26.50% | -6.75% | +52.87% | +352.96% | |
Net Margin Growth
| -18.01% | -11.00% | -3.39% | +6.67% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (42.04M) | (44.88M) | (21.15M) | 53.51M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (42.04M) | (44.88M) | (21.15M) | 53.51M | |
EPS (Basic)
| -1.5421 | -1.5988 | -0.7219 | 1.7978 | |
EPS (Basic) Growth
| +29.71% | -3.68% | +54.85% | +349.04% | |
Basic Shares Outstanding
| 27.26M | 28.07M | 29.30M | 29.76M | |
EPS (Diluted)
| -1.5421 | -1.5988 | -0.7219 | 1.7519 | |
EPS (Diluted) Growth
| +29.71% | -3.68% | +54.85% | +342.68% | |
Diluted Shares Outstanding
| 27.26M | 28.07M | 29.30M | 30.54M | |
EBITDA
| (37.86M) | (44.69M) | (37.42M) | 42.63M | |
EBITDA Growth
| +30.40% | -18.05% | +16.26% | +213.92% | |
EBITDA Margin
| -16.22% | -10.96% | -5.99% | +5.31% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 125.688 | |
| Number of Ratings | 19 | Current Quarters Estimate | 0.079 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 1.762 | |
| Last Quarter’s Earnings | 0.669 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.508 | Next Fiscal Year Estimate | 2.561 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 14 | 14 | 18 | 16 |
| Mean Estimate | 0.08 | 0.37 | 1.76 | 2.56 |
| High Estimates | 0.41 | 0.56 | 2.31 | 3.56 |
| Low Estimate | -0.33 | 0.24 | 1.36 | 1.61 |
| Coefficient of Variance | 298.37 | 30.93 | 15.76 | 21.47 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 11 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 9 | 9 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Inspire Medical Systems Inc - INSP
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Inspire Medical Systems Inc - INSP
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 21, 2026 | Casey M Tansey Director | 22,416 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $96.47 per share | 2,162,471.52 |
| Jan 13, 2026 | John C. Rondoni See Remarks | 13,797 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100 per share | 1,379,700.00 |
| Dec 5, 2025 | Shawn T. McCormick Director | 24,846 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $139 per share | 3,453,594.00 |
| Mar 6, 2025 | Randall A. Ban See Remarks | 7,259 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $187.08 per share | 1,358,013.72 |
| Mar 6, 2025 | Randall A. Ban See Remarks | 7,737 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $186.2 per share | 1,440,629.40 |
| Mar 6, 2025 | Randall A. Ban See Remarks | 8,970 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $185.37 per share | 1,662,768.90 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 36,126 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share | 6,735,692.70 |
| Feb 26, 2025 | John C. Rondoni Chief Technology Officer | 17,787 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share | 3,316,386.15 |
| Feb 26, 2025 | Timothy P. Herbert CEO and President; Director | 35,149 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share | 6,553,531.05 |
| Feb 26, 2025 | Timothy P. Herbert CEO and President; Director | 43,422 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Bryan K. Phillips See Remarks | 15,442 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 38,326 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 1,475 | Bona fide gift | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 1,475 | Bona fide gift | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 1,475 | Bona fide gift | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 1,475 | Bona fide gift | 0.00 |
| Feb 26, 2025 | Richard John Buchholz Chief Financial Officer | 32,174 | Bona fide gift | 0.00 |
| Feb 26, 2025 | Bryan K. Phillips See Remarks | 13,236 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share | 2,467,852.20 |